Novo Nordisk released the first top-line results from its STEP Young phase 3 trial this morning, and the headline number is going to be difficult to ignore. After 68 weeks, 40.4% of children ages 6 to under 12 treated with semaglutide were no longer classified as having obesity, compared with 0% of children receiving placebo.

I already know where a lot o…